Immunotherapy combo shows promise in esophageal cancer trial
NCT ID NCT03957590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tested whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy helps people with localized esophageal squamous cell carcinoma. 370 participants received either tislelizumab or a placebo alongside chemotherapy and radiation. The study measured how long patients lived without their cancer worsening and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab (an immunotherapy drug)
What this could lead to
If successful, this could offer a new treatment option that helps control localized esophageal cancer for longer.
What could go wrong
This is a completed phase 3 trial, but results are not yet widely available. Immunotherapy can cause immune-related side effects, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212001, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Changzhou Tumor(Fourth Peoples)Hospital
Changzhou, Jiangsu, 213000, China
-
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Hangzhou Cancer Hospital
Hangzhou, Zhejiang, 310002, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, 046000, China
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Inner Mongolia Autonomous Region Cancer Hospital
Hohhot, Inner Mongolia, 010028, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Jieyang Peoples Hospital (Jieyang Affiliated Hospital, Sun Yat Sen University )
Jieyang, Guangdong, 522000, China
-
Jinhua Municipal Central Hospital
Jinhua, Zhejiang, 321000, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Northern Jiangsu Peoples Hospital
Yangzhou, Jiangsu, 225001, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Sichuan Cancer Hospital and Institute
Chengdu, Sichuan, 610041, China
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221000, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
-
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, 710061, China
-
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, 453100, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The First Affiliated Hospitalschool of Clinical Medicine of Guangdong Pharmaceutical University
Guangzhou, Guangdong, 510000, China
-
The First Peoples Hospital of Lianyungang
Lianyungang, Jiangsu, 222002, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
Weifang Peoples Hospital
Weifang, Shandong, 261000, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China